Search
Sunday 31 January 2016
  • :
  • :

Skyrocketing Stocks Alert: Novogen Limited (ADR) (NASDAQ:NVGN), Vitesse Semiconductor (NASDAQ:VTSS), Retrophin Inc (NASDAQ:RTRX), Mechel OAO (ADR) (NYSE:MTL)

Skyrocketing Stocks Alert: Novogen Limited (ADR) (NASDAQ:NVGN), Vitesse Semiconductor (NASDAQ:VTSS), Retrophin Inc (NASDAQ:RTRX), Mechel OAO (ADR) (NYSE:MTL)

Following U.S. Stocks are among the “Top Gainers” Stocks in the course of recent trading session, Wednesday: Novogen Limited (ADR) (NASDAQ:NVGN), Vitesse Semiconductor (NASDAQ:VTSS), Retrophin Inc (NASDAQ:RTRX), Mechel OAO (ADR) (NYSE:MTL)

Novogen Limited (ADR) (NASDAQ:NVGN), declared on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell’s cytoskeleton can deliver a powerful anti-cancer effect.

Dr Kelly was interviewed by Channel 7 health reporter, Dr Andrew Rochford about Anisina’s potential.

Novogen Limited (ADR) (NASDAQ:NVGN)’s shares skyrocketed 38.51%, and is now trading at $4.30. The Stock is active as 2.41M shares changed hands versus its average volume of 990,161.00 shares. The stock has price to sale ratio of 21.23, however, price to book ratio is 17.11. With recent incline, the year-to-date (YTD) performance reflected a 48.08% gain above last year. During the past month the stocks gain 10.39%, bringing three-month performance to 87.80% and six-month performance to -5.52%.

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which comprise Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, counting glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Vitesse Semiconductor (NASDAQ:VTSS), and Microsemi Corporation (MSCC) jointly recently declared that Microsemi has reached a definitive contract to attain Vitesse for $5.28 per share through a cash tender offer, representing a premium of 32 percent based on the average closing price of Vitesse’s shares of ordinary stock during the 30 trading days ended March 17, 2015. The board of directors of Vitesse unanimously recommends that Vitesse’s stockholders tender their shares in the tender offer. The total transaction value is about $389 million.

Vitesse Semiconductor (NASDAQ:VTSS), raised 36.25%, and is now trading at $5.31, hitting new 52-week high of $5.34. The company holds the market capitalization of $366.37M. For the last twelve months, the stock was able to keep return on equity at -73.10%, while return on assets at -19.90%, in response to its return on investment at -14.60%. Its 20-day moving average gained 30.74%, above 50-day moving average of 32.73%, above 200-day moving average of 50.36% from the latest market price of $5.31. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).

Vitesse Semiconductor Corporation designs, develops, and markets various semiconductor products for carrier and enterprise networking applications worldwide. The company provides carrier Ethernet switch engines, counting mobile access equipment, such as base stations, small cells, fiber and microwave wireless backhaul products, and Ethernet access devices for delivering business services; and enterprise Ethernet switches for cloud access, desktop, workgroup, and LAN infrastructure to migrate to gigabit Ethernet speeds. It also offers gigabit Ethernet copper and dual-media transceivers, counting single, quad, and octal devices that allow transmission of 10/100/1000 BASE-T data over category 5 copper cable and fiber optic cabling for use in personal computing, home electronics, and LAN applications; and SynchroPHY gigabit Ethernet copper and dual-media transceivers.

Retrophin Inc (NASDAQ:RTRX), recently stated that the U.S. Food and Drug Administration (FDA) has accepted Cholbam (cholic acid) capsules, the first FDA approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders.

Retrophin Inc (NASDAQ:RTRX), enhanced 27.17%, and is now trading at $18.77. The stock volatility for the week is 6.61%, while for the month remained 6.70%. The company holds consensus target price of $39.00.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed -4.16 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 71.30% and Annual EPS growth for the past 5 years is considered as -69.50%.

The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).

Retrophin, Inc., a biopharmaceutical company, focuses on the development, attainment, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders; and Thiola for the treatment of cystinuria. The company also develops Sparsentan, an investigational therapeutic agent, which acts as a potent angiotensin receptor blocker, in addition to endothelin receptor antagonist for the treatment of focal segmental glomerulosclerosis; RE-024, a novel small molecule to treat pantothenate kinase associated neurodegeneration; and Carbetocin for the treatment of milk let-down in post pregnant women, in addition to for autism and schizophrenia. In addition, it develops RE-034, a synthetic hormone analogue of the first 24 amino acids of the 39 amino acids contained in adrenocorticotrophic hormone for the treatment of infantile spasms and nephrotic syndrome.

Mechel OAO (ADR) (NYSE:MTL), picked up 19.42%, and is now trading at $1.23. The company has the market capitalization of $718.31M. The beta value of the stock is 2.13. On the other hand the stock’s volatility for the week is 20.92%, and for the month is 10.65%. The stock’s price to sale ratio is $0.07, however price to cash ratio is $6.35. Analyst’s mean recommendation regarding this stock is 3.70. (where 1=Buy, 5=Sale).

Mechel OAO, together with its subsidiaries, is engaged in mining and steel businesses in the Russian Federation, other CIS countries, Europe, Asia, the Middle East, and internationally. The company operates through four segments: Mining, Steel, Ferroalloys, and Power. The Mining segment is engaged in the production and sale of metallurgical and steam coal, coke, iron ore, and limestone, in addition to chemical products, such as coal tar, naphthalene, and other compounds. The Steel segment produces and sells semi-finished steel products, carbon and special long products, and carbon and stainless flat products, in addition to metal products, counting forgings, stampings, and wire products. The Ferroalloys segment is involved in the production and sale of ferrosilicon. The Power segment is engaged in the generation and sale of electricity and heat energy from steam coal; and power distribution activities. The company, formerly known as Mechel Steel Group OAO, was founded in 2003 and is based in Moscow, the Russian Federation.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.